Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 441-448

  Van Moorsel, C J A ^a   Kroep, J R ^a   Pinedo, H M ^a   Veerman, G ^a   Voorn, D A ^a   Postmus, P E ^b   Vermorken, J B ^b   Van Groeningen, C J ^a   Van Der Vijgh, W J F ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Medical Oncology ^*

Author keywords

Cisplatin; dFdCTP accumulation; Gemcitabine; Pharmacodynamics; Pharmacokinetics; Phase I study; Pt DNA adducts

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DNA ADDUCT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LUNG CARCINOMA; MALE; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0032939255     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008301522349     Document Type: Article

References (51)

1. Scanlon KJ, Kashai-Sabet M, Tone Tet al. Cisplatin resistance in human cancers. Pharmacol Ther 1991; 52: 385-406.
2. Fichtinger-Schepman AMJ, Van der Veer JL et al. Adducts of the antitumor drug cis-diammine-dichloroplatinum (II) with DNA: Formation, identification, and quantification. Biochemistry 1985; 24: 707-13.
3. Terheggen PMAN, Edmondt JY, Floot BGJ et al. Correlation between cell killing by cisdiamminedichloroplatinum(II) in six mammalian cell lines and binding of a cisdiamminedichloroplatinum(II)-DNA antiserum. Cancer Res 1990; 50: 3556-61.
4. Parker RJ, Gill I, Tarone R et al. Platinum DNA-damage in leukocyte DNA of patients receiving cisplatin and carboplatin chemotherapy, measured by atomic absorpotion spectrometry. Carcinogenesis 1991; 12: 1253-8.
5. Schellens JHM, Ma J, Planting ASTh et al. Relationship between the exposure to cisplatin, DNA adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996; 73: 1569-75.
6. Reed E, Yuspa SH, Zwelling LA et al. Quantification of cisdiammine-dichloroplatinum II (cisplatin)-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 1987; 77: 545-50.
7. Reed E, Ozols RF, Tarone R et al. The measurements of cisDDP-DNA adduct levels in testicular cancer patients. Carcinogenesis 1988; 9: 1909-11.
8. Reed E, Ostchega Y, Steinberg SM et al. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990; 50: 2256-60.
9. Hertel LW, Kroin JS, Misner JW et al. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J Org Chem 1988; 53: 2406-9.
10. Van Moorsel CJA, Peters GJ, Pinedo HM. Gemcitabine: Future prospects of single-agent and combination studies. The Oncologist 1997; 2: 127-34.
11. Huang P, Chubb S, Hertel LW et al. Action of 2′,2′-difluoro-deoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
12. Heinemann V, Hertel LW, Grindey GB et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-31.
13. Baker CH, Bazon J, Bollinger JM et al. 2′-deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorodeoxycytidine 5′diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 1991; 34: 1879-84.
14. Peters GJ, Bergman AM, Ruiz van Haperen VWT et al. Interaction between gemcitabine and cisplatin in vitro and in vivo. Semin Oncol 1995; 22 (Suppl II): 72-9.
15. Bergman AM, Ruiz van Haperen VWT, Veerman G et al. Interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996; 2: 521-30.
16. Van Moorsel CJA, Pinedo HM, Veerman G et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999 (in press)
17. Braakhuis BJM, Ruiz van Haperen VWT, Welters MJP et al. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995; 31A: 1335-40.
18. Van Moorsel CJA, Pinedo HM, Veerman G et al. Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice. Eur J Cancer 1999 (in press).
19. Tanzer LR, Rutherford PG, Self TD et al. Antitumor activity of gemcitabine in combination with cisplatin against the human NSCLC xenograft Calu-6. Proc AACR 1995; 36: 296 (Abstr 1761).
20. Green MR, Eisenberg P, Kosty M et al. Activity and tolerability of gemcitabine plus weekly cisplatin in advanced non-small-cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 1998; 17: 468 (Abstr 1798).
21. Lippe P, Tummarrello D, Monterubbianesi MC et al. Weekly gemcitabine (GEM) and cisplatin (PL) in advanced non-small-cell lung cancer (ANSCLC). Proc Annu Meet Am Soc Clin Oncol 1998; 17: 494 (Abstr 1902).
22. Shepherd FA, Cormier Y, Burkes R et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer. Semin Oncol 1997; 24 (Suppl 8): 27-30.
23. Crinò L, Scagliotto G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997; 15: 297-303.
24. Rinaldi M, Crinò L, Scagliotti G et al. A new schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer (NSCLC) with two different cisplatin dose levels: A phase II randomized trial. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 470 (Abstr 1807).
25. Cartei G, Sacco C, Cioschi B et al. Gemcitabine (G) and platin (P) in advanced non-small cell lung cancer (NSCLC): A phase II study with emphasis on intention-to-treat analysis. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 467 (Abstr 1795).
26. Anton A, Carrato A, Gonzalez Larriba JL et al. Phase II activity of gemcitabine in combination with cisplatin in advanced non-small-cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 15 1996; 15: 380 (Abstr 1134).
27. Abratt RP, Bezwoda WR, Goedhals L et al. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15: 744-9.
28. Steward WP, Dunlop DJ, Dabouis G et al. Phase I-II study of gemcitabine and cisplatin in non-small-cell lung cancer: Preliminary results. Semin Oncol 1996; 5 (Suppl 10): 43-7.
29. Einhorn LH. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: A Hoosier Oncology Group study. Semin Oncol 1997; 24 (Suppl 8): 24-6.
30. Gonzàlez-Baròn M, Ordonze A, Gracia M et al. Gemcitabine and cisplatin in advanced non-small-cell lung cancer (NSCLC): Results from a phase II study. Proc Annu Meet Am Soc Clin Oncol 1997; 16:469 (Abstr 1687).
31. Sandler A, Nemunaitis J, Dehnam C et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small-cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 1998; 17: 454 (Abstr 1747).
32. Krakowski I, Petit T, Kayitalire L et al. Gemcitabine (Gemzar®) in combination with cisplatin (CP) in advanced ovarian cancers (AOC): A phase II study. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 356 (Abstr 1373).
33. Bauknecht T, Grieshaber Ch, Breitbach G-P et al. Gemcitabine (GEM) in combination with cisplatin (CP) in previously untreated patients ≥ 60 years with FIGO stage IIIC or IV epithelial ovarian cancer: A phase II study: Preliminary results. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 356 (Abstr 1376).
34. Nogué M, Cirera L, Arcusa M et al. Gemcitabine combined with cisplatin first line: A phase II study in patients with advanced epithelial ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 357 (Abstr 1377).
35. Kunkel LM, Evans SS, Dottino PR et al. Cisplatin (CDDP) & gemcitabine (dFdC) in relapsed ovarian cancer. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 357 (Abstr 1379).
36. Von der Maasse H, Andersen L, Crino L et al. A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc Annu Meet Am Soc Clin Oncol 1997; 16: 324 (Abstr 1155).
37. Moore MJ, Tannock I, Winquist E et al. Gemcitabine (GEM) + cisplatin (C): An active regimen in advanced transitional cell carcinoma (TCC). Proc Annu Meet Am Soc Clin Oncol 1998; 17: 320 (Abstr 1234).
38. Kaufman D, Stadler W, Carducci M et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): Final results of a phase II study. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 320 (Abstr 1235).
39. Colucci G, Giuliani F, Riccardi F et al. Gemcitabine alone or with cisplatin in advanced pancreatic cancer: Preliminary results of a randomized study of the Southern Italy Oncology Group. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 289 (Abstr 1112).
40. Peters GJ, Tanis B, Clavel M et al. Pharmacokinetics of Gemcitabine (LY188011; difluorodeoxycytidine) administered every two weeks in a phase I study. Proc Am Assoc Cancer Res 1990; 31: 180.
41. Peters GJ, Schwartsmann G, Nadal JC et al. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res 1990; 50: 4644-9.
42. Peters GJ, Van Groeningen CJ, Laurensse E et al. Uridine induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol 1987; 20: 101-8.
43. Korst AE, Van der Sterre ML, Gall HE et al. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 1998; 4: 331-6.
44. Ruiz van Haperen VWT, Veerman G, Boven E et al. Schedule-dependence of sensitivity to 2′,2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol 1994; 48: 1327-9.
45. Blommaert FA, Saris CP. Detection of platinum-DNA adducts by 32P-postlabelling. Nucl Acids Res 1995; 23:1300-6.
46. Welters MJP, Maliepaard M, Jacobs-Bergmans AJ et al. Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts. Carcinogenesis 1997; 18: 1767-74.
47. Abbruzesse JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
48. Fichtinger Schepman AMJ, Van Dijk-Knijnenburg HCM, Van der Velde-Visser SD et al. Cisplatin- and carboplatin-DNA adducts: Is the Pt-AG the cytotoxic lesion? Carcinogenesis 1995; 16: 2447-53.
49. Sancar A, Tang M-S. Nucleotide excision repair. Photochem Photobiol 1993; 57: 905-21.
50. Fracasso ME, Apostoli P, Benoni G et al. Kinetics of platinum in cancer patients treated with cisplatin at different doses. Drugs Exp Clin Res 1987; 13: 367-72.
51. Fichtinger-Schepman AMJ, Van Oosterom AT, Lohman PHM et al. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes form seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 1987; 47: 3000-4.